サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1786353

サイバーナイフの世界市場

CyberKnife

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
サイバーナイフの世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

サイバーナイフの世界市場は2030年までに17億米ドルに達する見込み

2024年に6億1,840万米ドルと推定されるサイバーナイフの世界市場は、2024～2030年の分析期間においてCAGR 18.5％で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるがんアプリケーションは、CAGR 20.0％を記録し、分析期間終了までに11億米ドルに達すると予測されます。腫瘍アプリケーション分野の成長率は、分析期間中CAGR 17.3％と推定されます。

米国市場は1億6,850万米ドルと推定、中国はCAGR24.5％で成長予測

米国のサイバーナイフ市場は、2024年に1億6,850万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを24.5%として、2030年までに3億8,750万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に13.6%と16.8%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約14.8%で成長すると予測されています。

世界のサイバーナイフ市場- 主要動向と市場促進要因のまとめ

サイバーナイフが精密放射線治療で認知される理由とは？

最先端のロボット放射線手術システムであるサイバーナイフは、非侵襲的で高精度な放射線治療を提供することで、がん治療に革命をもたらしました。従来の放射線技術とは異なり、サイバーナイフはリアルタイムの画像ガイダンスとロボット技術を駆使して、ミリメートル以下の精度で腫瘍を狙い撃ちし、周囲の健康な組織へのダメージを最小限に抑えます。これにより、脳腫瘍、前立腺がん、肺がん、脊椎がん、膵臓がんなど、複雑ながんの治療に欠かせないツールとなっています。

世界のがん罹患率の増加により、高度な放射線治療ソリューションへの需要が高まっており、サイバーナイフは痛みのない外来ベースの治療を求める患者にとって好ましい選択肢として浮上しています。サイバーナイフは、特に肺がんや前立腺がんなどの患者の動きに適応できるため、治療効果と患者の快適性が向上します。さらに、定位体放射線治療（SBRT）と定位放射線手術（SRS）の採用が増加しており、世界中の主要な腫瘍センターでサイバーナイフシステムの統合が推進されています。

サイバーナイフシステムの最新技術進歩とは？

ロボット放射線手術における絶え間ない技術革新は、サイバーナイフの能力を大幅に向上させ、治療の正確性、効率性、安全性を高めました。最も注目すべき進歩の1つは、AIによる腫瘍追跡機能を統合したことで、患者の動きに基づいて放射線ビームをリアルタイムで調整できるようになりました。これは、呼吸運動がターゲティング精度に影響を与える可能性のある肺などの移動性臓器の腫瘍治療に特に有益です。

もうひとつのブレークスルーは、より高い線量をより短い治療時間で照射し、必要な治療回数を減らす次世代リニアック（線形加速器）の開発です。さらに、MRIガイド下放射線手術や適応放射線治療などの高度な画像診断がサイバーナイフシステムと統合され、治療計画の精緻化と臨床成績の向上が図られています。また、クラウドベースの治療計画や遠隔モニタリング機能も拡大しており、腫瘍内科医が遠隔で協力して治療プロトコルを調整できるようになっています。

市場動向とヘルスケア政策は、サイバーナイフ導入にどのような影響を与えていますか？

サイバーナイフの採用は、非侵襲的ながん治療へのシフト、患者中心の治療への注目の高まり、放射線手術の保険適用範囲の拡大など、進化するヘルスケア動向によって形成されています。新興市場におけるヘルスケアインフラの拡大もサイバーナイフの普及に寄与しており、病院はがん治療需要の高まりに対応するために最先端の腫瘍学ソリューションに投資しています。

FDAや欧州医薬品庁（EMA）などの規制機関は、放射線治療システムの安全性と有効性を確保するためのガイドラインを継続的に更新しています。このような規制により、サイバーナイフメーカーは品質管理を強化し、AIを活用した安全メカニズムを開発し、国際的な放射線治療基準へのコンプライアンスを向上させる必要に迫られています。さらに、サイバーナイフの有効性を裏付ける臨床研究の増加により、主要な放射線手術ソリューションとしての地位が強化されています。

サイバーナイフ市場の成長の原動力は？

サイバーナイフ市場の成長の原動力は、ロボット放射線手術の進歩、がん罹患率の増加、非侵襲的治療法への嗜好の高まりです。より多くのヘルスケアプロバイダーが精密放射線治療の利点を認識するようになり、サイバーナイフシステムへの投資は先進国、発展途上国を問わず拡大しています。

神経外科、整形外科、小児放射線治療では、より精密で低侵襲な治療のためにサイバーナイフが採用されています。患者や腫瘍医の間でサイバーナイフの認知度が高まっていることも、特に治療成績が生存率の向上と副作用の軽減を実証し続けていることから、市場の成長を後押ししています。さらに、ヘルスケアプロバイダーと放射線治療技術企業間のパートナーシップがイノベーションを促進し、アクセシビリティを向上させ、サイバーナイフ治療プロトコルの継続的な進歩を確実なものにしています。

セグメント

用途（がん用途、腫瘍用途、血管奇形用途、その他用途）;最終用途（病院最終用途、外来患者施設最終用途、調査・製造最終用途）

調査対象企業の例

  • Apollo Hospitals
  • Azienda Ospedaliera di Padova
  • Centre Oscar Lambret
  • Charite-Universitatsmedizin Berlin
  • Clinica Universidad de Navarra
  • CyberKnife Center at Mercy Hospital
  • CyberKnife Center Munich
  • CyberKnife Center of Miami
  • CyberKnife Center of Southern California
  • Hopital Europeen Georges-Pompidou
  • Instituto de Radiocirugia CyberKnife IRCA
  • National Cancer Centre Singapore
  • Ospedale San Raffaele
  • Providence Swedish Radiosurgery Center
  • Samsung Medical Center
  • Stanford Health Care
  • Tata Memorial Hospital
  • The Harley Street Clinic
  • Universitatsklinikum Heidelberg
  • University College Hospital London

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30332

Global CyberKnife Market to Reach US$1.7 Billion by 2030

The global market for CyberKnife estimated at US$618.4 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 18.5% over the analysis period 2024-2030. Cancer Application, one of the segments analyzed in the report, is expected to record a 20.0% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Tumor Application segment is estimated at 17.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.5 Million While China is Forecast to Grow at 24.5% CAGR

The CyberKnife market in the U.S. is estimated at US$168.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$387.5 Million by the year 2030 trailing a CAGR of 24.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global CyberKnife Market - Key Trends & Growth Drivers Summarized

Why Is CyberKnife Gaining Recognition in Precision Radiation Therapy?

CyberKnife, a state-of-the-art robotic radiosurgery system, has revolutionized cancer treatment by offering non-invasive, high-precision radiation therapy. Unlike traditional radiation techniques, CyberKnife utilizes real-time image guidance and robotic technology to target tumors with sub-millimeter accuracy, minimizing damage to surrounding healthy tissues. This has made it an essential tool in treating complex cancers, including brain, prostate, lung, spine, and pancreatic tumors.

The rising global cancer burden has intensified the demand for advanced radiotherapy solutions, with CyberKnife emerging as a preferred alternative for patients seeking pain-free, outpatient-based treatment. Its ability to adapt to patient movement, particularly in lung and prostate cancer cases, enhances treatment efficacy and patient comfort. Additionally, the growing adoption of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) has propelled the integration of CyberKnife systems in leading oncology centers worldwide.

What Are the Latest Technological Advancements in CyberKnife Systems?

Continuous innovation in robotic radiosurgery has significantly improved CyberKnife’s capabilities, enhancing treatment accuracy, efficiency, and safety. One of the most notable advancements is the integration of AI-driven tumor tracking, allowing real-time adjustments to radiation beams based on patient movement. This is particularly beneficial for treating tumors in mobile organs, such as the lungs, where respiratory motion can affect targeting precision.

Another breakthrough is the development of next-generation linear accelerators, which deliver higher radiation doses in shorter treatment times, reducing the number of sessions required. Additionally, advanced imaging modalities, including MRI-guided radiosurgery and adaptive radiotherapy, are being integrated with CyberKnife systems to refine treatment planning and improve clinical outcomes. Cloud-based treatment planning and remote monitoring capabilities are also expanding, allowing oncologists to collaborate and adjust treatment protocols remotely.

How Are Market Trends and Healthcare Policies Influencing CyberKnife Adoption?

The adoption of CyberKnife is being shaped by evolving healthcare trends, including the shift toward non-invasive cancer treatments, increased focus on patient-centered care, and growing reimbursement coverage for radiosurgery procedures. The expansion of healthcare infrastructure in emerging markets has also contributed to CyberKnife’s adoption, as hospitals invest in cutting-edge oncology solutions to meet rising cancer treatment demands.

Regulatory agencies, including the FDA and the European Medicines Agency (EMA), are continuously updating guidelines to ensure the safety and efficacy of radiation therapy systems. These regulations have driven CyberKnife manufacturers to enhance quality control, develop AI-driven safety mechanisms, and improve compliance with international radiation therapy standards. Additionally, the rising number of clinical studies supporting CyberKnife’s efficacy is strengthening its position as a leading radiosurgery solution.

What Is Driving the Growth of the CyberKnife Market?

The growth in the CyberKnife market is driven by advancements in robotic radiosurgery, increasing cancer incidence rates, and the growing preference for non-invasive treatment modalities. As more healthcare providers recognize the benefits of precision radiation therapy, investments in CyberKnife systems are expanding across developed and developing regions.

End-use expansion is another key factor, with neurosurgery, orthopedic oncology, and pediatric radiation therapy incorporating CyberKnife for more precise, minimally invasive treatments. The rising awareness of CyberKnife among patients and oncologists is also fueling market growth, particularly as treatment outcomes continue to demonstrate improved survival rates and reduced side effects. Additionally, partnerships between healthcare providers and radiotherapy technology firms are fostering innovation, enhancing accessibility, and ensuring continued advancements in CyberKnife treatment protocols.

SCOPE OF STUDY:

The report analyzes the CyberKnife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Cancer Application, Tumor Application, Vascular Malformation Application, Other Applications); End-Use (Hospitals End-Use, Outpatient Facilities End-Use, Research and Manufacturing End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Apollo Hospitals
  • Azienda Ospedaliera di Padova
  • Centre Oscar Lambret
  • Charite - Universitatsmedizin Berlin
  • Clinica Universidad de Navarra
  • CyberKnife Center at Mercy Hospital
  • CyberKnife Center Munich
  • CyberKnife Center of Miami
  • CyberKnife Center of Southern California
  • Hopital Europeen Georges-Pompidou
  • Instituto de Radiocirugia CyberKnife IRCA
  • National Cancer Centre Singapore
  • Ospedale San Raffaele
  • Providence Swedish Radiosurgery Center
  • Samsung Medical Center
  • Stanford Health Care
  • Tata Memorial Hospital
  • The Harley Street Clinic
  • Universitatsklinikum Heidelberg
  • University College Hospital London

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • CyberKnife - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Globally Fuels Adoption of Non-Invasive Radiosurgical Solutions Like CyberKnife
    • Growing Patient Preference for Precision, Painless, Outpatient Treatments Strengthens CyberKnife Utilization
    • Advancements in Real-Time Tumor Tracking and Adaptive Radiotherapy Enhance Clinical Outcomes
    • OEM Innovation in Image-Guided Robotic Systems Propels CyberKnife Over Conventional Linac Systems
    • Increased Deployment in Private Cancer Care Chains and Specialty Oncology Centers Drives Market Expansion
    • FDA and CE Mark Approvals for Expanded Indications Accelerate Global CyberKnife Adoption
    • Integration With Treatment Planning and AI-Powered Dosimetry Systems Improves Accuracy and Efficiency
    • Growing Use in Intracranial, Spinal, Lung, and Prostate Tumors Broadens Application Scope
    • Rising Referrals From Neurosurgeons and Radiation Oncologists Boost Clinical Awareness and Volume
    • OEM Expansion Into Emerging Markets Supports Access to Robotic Radiosurgery Technology
    • Favorable Reimbursement for Radiosurgery in Developed Markets Enhances Adoption Rates
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CyberKnife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for CyberKnife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vascular Malformation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Vascular Malformation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Outpatient Facilities End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Outpatient Facilities End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research & Manufacturing End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Research & Manufacturing End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for CyberKnife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for CyberKnife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for CyberKnife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for CyberKnife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for CyberKnife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • CyberKnife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for CyberKnife by Application - Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for CyberKnife by Application - Percentage Breakdown of Value Sales for Cancer Application, Tumor Application, Vascular Malformation Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for CyberKnife by End-Use - Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for CyberKnife by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Outpatient Facilities End-Use and Research & Manufacturing End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION